Rita Andraos

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Adrian Britschgi, Rita Andraos, Heike Brinkhaus et al. · Cancer Cell · 2012 · 242 citations · Full text

Medicine, Oncology, Pharmacology +16

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 155 citations

Medicine, Pharmacology, Pharmacotherapy +13

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Rita Andraos, Zhiyan Qian, Débora Bonenfant et al. · Cancer Discovery · 2012 · 130 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp et al. · Cancer Cell · 2015 · 123 citations · Full text

Medicine, Oncology, Pharmacology +8

Enhanced sensitivity to IGF-II signaling links loss of imprinting of <i>IGF2</i> to increased cell proliferation and tumor risk

Atsushi Kaneda, Chiaochun J. Wang, Raymond Cheong et al. · Proceedings of the National Academy of Sciences · 2007 · 101 citations

Life Sciences, Genetics, Oncology +17